Ayumi Ando

Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response

Akito Nakamura, Tadahiro Nambu, Shunsuke Ebara et al. · Proceedings of the National Academy of Sciences · 2018 · 160 citations · Full text

Tumor Biology, Oncology, Amino Acid Response +14

Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions

Saomi Murai, Ayumi Ando, Shunsuke Ebara et al. · Oncogenesis · 2017 · 79 citations · Full text

Oncology, Biochemistry, Oncogenic Agent +15

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors

Takatsugu Okegawa, Megumi Morimoto, Satoru Nishizawa et al. · EBioMedicine · 2017 · 68 citations · Full text

Pathology, Metabolic Remodeling, Tumor Biology +21

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors

Satoshi Kitazawa, Shunsuke Ebara, Ayumi Ando et al. · Oncotarget · 2017 · 33 citations · Full text

A novel and selective melanin-concentrating hormone receptor 1 antagonist ameliorates obesity and hepatic steatosis in diet-induced obese rodent models

Y. Kawata, Shoki Okuda, Natsu Hotta et al. · European Journal of Pharmacology · 2016 · 24 citations

Obesity, Metabolic Syndrome, Medicine +11